Chelsea Counsel Company’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Chelsea Counsel Company’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-650	Closed	-$3K	–	89
2016 Q3	$3K	Hold	650	–	–	﹤0.01%	88
2016 Q2	$6K	Sell	650 -50	-7%	-$514	﹤0.01%	95
2016 Q1	$8K	Hold	700	–	–	﹤0.01%	126
2015 Q4	$10K	Hold	700	–	–	﹤0.01%	135
2015 Q3	$12K	Hold	700	–	–	﹤0.01%	156
2015 Q2	$13K	Hold	700	–	–	﹤0.01%	159
2015 Q1	$14K	Hold	700	–	–	﹤0.01%	137
2014 Q4	$20K	Hold	700	–	–	﹤0.01%	134
2014 Q3	$25K	Hold	700	–	–	0.01%	131
2014 Q2	$31K	Hold	700	–	–	0.01%	124
2014 Q1	$34K	Hold	700	–	–	0.01%	121
2013 Q4	$26K	Hold	700	–	–	0.01%	110
2013 Q3	$72K	Hold	700	–	–	0.01%	111
2013 Q2	$54K	Buy	+700	New	+$67K	0.01%	101

Other funds holding IMUC

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Chelsea Counsel Company's IMUC Position: Q4 2016 in Review

Chelsea Counsel Company sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 650 shares — an estimated $3K sold.

Chelsea Counsel Company first reported a position in IMUC in Q2 2013 and held it in 14 quarters. The position peaked at $72K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

Chelsea Counsel Company reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
Chelsea Counsel Company sold 650 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $3K.
Chelsea Counsel Company first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 14 quarters.
Chelsea Counsel Company's ImmunoCellular Therapeutics, Ltd. position peaked at $72K in Q3 2013.
16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Chelsea Counsel Company's 13F filing for Q4 2016, filed 20 Apr 2017.